ReviewTherapeutic advances in medical oncology2017
Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy.
Review in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO-Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non-Small Cell Lung Cancer.Human mutation · 2026Article
- A Comprehensive Review on the Application of Artificial Intelligence for Predicting Postsurgical Recurrence Risk in Early-Stage Non-Small Cell Lung Cancer Using Computed Tomography, Positron Emission Tomography, and Clinical Data.Journal of medical radiation sciences · 2025Review
- Factors affecting accuracy of clinical staging in resectable non-small cell lung cancer in a real-world study.Thoracic cancer · 2024Article
- Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.Journal of comparative effectiveness research · 2023Article
- The Usefulness of the Ratio of Antigen-Autoantibody Immune Complexes to Their Free Antigens in the Diagnosis of Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- Automated lung cancer assessment on 18F-PET/CT using Retina U-Net and anatomical region segmentation.European radiology · 2023Article
- Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study.Molecular oncology · 2023Article
- Review
- Article
- A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region.PloS one · 2023Article
- Change in treatment modality and trends in survival among stage I non-small cell lung cancer patients: a population-based study.Journal of thoracic disease · 2020Article
- miR-410 induces both epithelial-mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer.Signal transduction and targeted therapy · 2020Article
- The association of nodal upstaging with surgical approach and its impact on long-term survival after resection of non-small-cell lung cancer.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2020Article
- The multidisciplinary team plays an important role in the prediction of small solitary pulmonary nodules: a propensity-score-matching study.Annals of translational medicine · 2019Article
- DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.Journal of cellular and molecular medicine · 2019Article
- Is there a role for upfront surgery in patients with N2 disease and good prognostic features?Journal of thoracic disease · 2019Article
- Prodigiosin-Emerged PI3K/Beclin-1-Independent Pathway Elicits Autophagic Cell Death in Doxorubicin-Sensitive and -Resistant Lung Cancer.Journal of clinical medicine · 2018Article
- Invited letter to the editor on the editorial on "Journal of thoracic disease · 2018Article
- New classification-new problems to solve.Journal of thoracic disease · 2018Article
- A dosimetric phantom study of thoracic radiotherapy based on three-dimensional modeling of mediastinal lymph nodes.Oncology letters · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I-III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy. For stage I disease, staging is most accurate. Primary treatment consists of surgery or stereotactic ablative radiotherapy. When a patient has stage II disease, staging is less accurate because more diagnostic modalities are necessary to stage the mediastinal lymph nodes. Surgery remains the primary treatment modality and platinum-based adjuvant chemotherapy gives a 4% 5-year survival benefit. Staging patients with stage III disease is difficult because of the heterogeneity of the patients. It should be decided if a patient has potentially resectable disease with or without risk of incomplete resection. Induction therapy with chemo(radio)therapy followed by surgical resection or definitive chemoradiotherapy are the treatments of choice. The 5-year survival can reach 44% in selected patients. Decisions in staging and treating patients with NSCLC should be made by a multidisciplinary team with sufficient expertise in all aspects of staging and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.